As of November 7, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Janux Therapeutics, Inc. The largest reported stake is BlackRock, Inc.'s, at 6.7%. 17 filings are on record since July 17, 2025 (Schedule 13G/A, July 28, 2026).
Sell to companies like Janux Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Point72 Asset Management, L.P. · Sole voting: 0 · Shared voting: 1,993,837 · Sole dispositive: 0 · Shared dispositive: 1,993,837 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: JANUS HENDERSON GROUP Ltd. · Sole voting: 0 · Shared voting: 172,229 · Sole dispositive: 0 · Shared dispositive: 172,229 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: BlackRock, Inc. · Sole voting: 4,024,396 · Shared voting: 0 · Sole dispositive: 4,098,457 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-28
- · Holder: Janus Henderson Group Plc · Percent: 6.9% · SCHEDULE 13G/A
- · Holder: State Street Corporation · Percent: 4.1% · SCHEDULE 13G
Janux Therapeutics, Inc. has 17 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 6.7% | 4,098,457 | SCHEDULE 13G/A, 2026-07-28 | 2026-06-30 |
| 5.3% | 3,157,220 | SCHEDULE 13G, 2026-02-06 | 2026-02-03 | |
| Paradigm BioCapital Advisors LP | 4.9% | 2,920,258 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Adage Capital Management, L.P. | 4.27% | 2,525,000 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| Fmr LLC | 4.2% | 2,535,724 | SCHEDULE 13G/A, 2026-05-06 | 2026-03-31 |
| State Street Corporation | 4.1% | 2,464,017 | SCHEDULE 13G, 2026-05-12 | 2026-03-31 |
| Point72 Asset Management, L.P. | 3.3% | 1,993,837 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| JANUS HENDERSON GROUP Ltd. | 0.3% | 172,229 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
Holding shares or following this stake? See who's behind Janux Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Janux Therapeutics, Inc. and the records around it.
Janux Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Prosight Management, LP also filed stake reports on 5 other companies: OnKure Therapeutics, Inc. (Aug 2026), ADC Therapeutics SA (Feb 2026), MeiraGTx Holdings plc (Feb 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
Watch Janux Therapeutics, Inc.
Get an email when Janux Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Janux Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Janux Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Janux Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,024,396 | 0 | 4,098,457 | 0 | SCHEDULE 13G/A, 2026-07-28 |
| Point72 Asset Management, L.P. | 0 | 1,993,837 | 0 | 1,993,837 | SCHEDULE 13G/A, 2026-08-14 |
| Point72 Capital Advisors, Inc. | 0 | 1,993,837 | 0 | 1,993,837 | SCHEDULE 13G/A, 2026-08-14 |
| Steven A. Cohen | 0 | 1,993,837 | 0 | 1,993,837 | SCHEDULE 13G/A, 2026-08-14 |
| JANUS HENDERSON GROUP Ltd. | 0 | 172,229 | 0 | 172,229 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Janux Therapeutics, Inc. by CUSIP 47103J105 and gives its principal executive office as 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA 92130 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 5.7% | SCHEDULE 13G |
| 2025-08-12 | Adage Capital Management, L.P. | 4.27% | SCHEDULE 13G/A |
| 2025-08-14 | Paradigm BioCapital Advisors LP | 4.9% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 7.5% | SCHEDULE 13G/A |
| 2025-11-07 | Janus Henderson Group Plc | 10% | SCHEDULE 13G/A |
| 2026-01-08 | Fmr LLC | 5.8% | SCHEDULE 13G/A |
| 2026-02-06 | W. Lawrence Hawkins | 5.3% | SCHEDULE 13G |
| 2026-02-09 | State Street Corporation | 6.4% | SCHEDULE 13G |
| 2026-02-17 | Janus Henderson Group Plc | 8.9% | SCHEDULE 13G/A |
| 2026-04-29 | Point72 Asset Management, L.P. | 5% | SCHEDULE 13G |
| 2026-04-29 | Point72 Asset Management, L.P. | 5% | SCHEDULE 13G |
| 2026-05-06 | Fmr LLC | 4.2% | SCHEDULE 13G/A |
| 2026-05-12 | State Street Corporation | 4.1% | SCHEDULE 13G |
| 2026-05-15 | Janus Henderson Group Plc | 6.9% | SCHEDULE 13G/A |
| 2026-07-28 | BlackRock, Inc. | 6.7% | SCHEDULE 13G/A |
| 2026-08-13 | JANUS HENDERSON GROUP Ltd. | 0.3% | SCHEDULE 13G/A |
| 2026-08-14 | Point72 Asset Management, L.P. | 3.3% | SCHEDULE 13G/A |
Questions about who owns Janux Therapeutics, Inc.
Who owns Janux Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Janux Therapeutics, Inc.: BlackRock, Inc. (6.7%, Schedule 13G/A, filed 2026-07-28) and W. Lawrence Hawkins (5.3%, Schedule 13G, filed 2026-02-06).
Who are the largest shareholders of Janux Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Janux Therapeutics, Inc. on this page are BlackRock, Inc. (6.7%) and W. Lawrence Hawkins (5.3%).
When did BlackRock, Inc. buy into Janux Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G, filed 2025-07-17, reporting 5.7%; its latest, Schedule 13G/A filed 2026-07-28, reports 6.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Janux Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 28, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Janux Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.